Current strategies of targeting neoantigens for cancer treatment are all based on TCRs that recognize mutant peptide/MHC complexes, because most of the neoantigens identified are expressed inside the tumor cells and processed and presented by MHC molecules (Gubin et al., 2014; Robbins et al., 2013; Tran et al., 2014). This evidence concerns the gene HLA-C and cancer.